These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 22837189)

  • 1. Polycystic ovary syndrome with hyperandrogenism is characterized by an increased risk of hepatic steatosis compared to nonhyperandrogenic PCOS phenotypes and healthy controls, independent of obesity and insulin resistance.
    Jones H; Sprung VS; Pugh CJ; Daousi C; Irwin A; Aziz N; Adams VL; Thomas EL; Bell JD; Kemp GJ; Cuthbertson DJ
    J Clin Endocrinol Metab; 2012 Oct; 97(10):3709-16. PubMed ID: 22837189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insulin resistance and hyperandrogenism drive steatosis and fibrosis risk in young females with PCOS.
    Petta S; Ciresi A; Bianco J; Geraci V; Boemi R; Galvano L; Magliozzo F; Merlino G; Craxì A; Giordano C
    PLoS One; 2017; 12(11):e0186136. PubMed ID: 29161258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endothelial dysfunction in hyperandrogenic polycystic ovary syndrome is not explained by either obesity or ectopic fat deposition.
    Sprung VS; Jones H; Pugh CJ; Aziz NF; Daousi C; Kemp GJ; Green DJ; Cable NT; Cuthbertson DJ
    Clin Sci (Lond); 2014 Jan; 126(1):67-74. PubMed ID: 23826984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polycystic ovary syndrome with feasible equivalence to overweight as a risk factor for non-alcoholic fatty liver disease development and severity in Mexican population.
    Salva-Pastor N; López-Sánchez GN; Chávez-Tapia NC; Audifred-Salomón JR; Niebla-Cárdenas D; Topete-Estrada R; Pereznuñez-Zamora H; Vidaltamayo-Ramírez R; Báez-Arellano ME; Uribe M; Nuño-Lámbarri N
    Ann Hepatol; 2020; 19(3):251-257. PubMed ID: 32111488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic characteristics of different phenotypes in reproductive-aged women with polycystic ovary syndrome.
    Wen X; Wang L; Bai E
    Front Endocrinol (Lausanne); 2024; 15():1370578. PubMed ID: 39109080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peri-muscular adipose tissue may play a unique role in determining insulin sensitivity/resistance in women with polycystic ovary syndrome.
    Morrison SA; Goss AM; Azziz R; Raju DA; Gower BA
    Hum Reprod; 2017 Jan; 32(1):185-192. PubMed ID: 27827322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic aspects of different phenotypes of polycystic ovary syndrome: Iranian PCOS Prevalence Study.
    Hosseinpanah F; Barzin M; Keihani S; Ramezani Tehrani F; Azizi F
    Clin Endocrinol (Oxf); 2014 Jul; 81(1):93-9. PubMed ID: 24428207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of fat to lean mass ratio with metabolic dysfunction in women with polycystic ovary syndrome.
    Ezeh U; Pall M; Mathur R; Azziz R
    Hum Reprod; 2014 Jul; 29(7):1508-17. PubMed ID: 24813197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgens exacerbate hepatic triglyceride accumulation in rats with polycystic ovary syndrome by downregulating MTTP expression.
    Wang D; Zhao H; Xing C; Lv B; Wang X; He B
    Endocrine; 2024 May; 84(2):735-744. PubMed ID: 37950821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alterations in nonesterified free fatty acid trafficking rather than hyperandrogenism contribute to metabolic health in obese women with polycystic ovary syndrome.
    Ezeh U; Chen YI; Pall M; Buyalos RP; Chan JL; Pisarska MD; Azziz R
    Fertil Steril; 2024 Jun; 121(6):1040-1052. PubMed ID: 38307453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin resistance and endocrine characteristics of the different phenotypes of polycystic ovary syndrome: a prospective study.
    Panidis D; Tziomalos K; Misichronis G; Papadakis E; Betsas G; Katsikis I; Macut D
    Hum Reprod; 2012 Feb; 27(2):541-9. PubMed ID: 22144419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of socio-demographic and clinical characteristics of PCOS patients attending a tertiary care institute in Colombo.
    Ranathunga I; Athukorala TG; Sumanatilleke MR; Somasundaram NP
    BMC Endocr Disord; 2022 Nov; 22(1):289. PubMed ID: 36411444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Body fat and insulin resistance independently predict increased serum C-reactive protein in hyperandrogenic women with polycystic ovary syndrome.
    Tosi F; Dorizzi R; Castello R; Maffeis C; Spiazzi G; Zoppini G; Muggeo M; Moghetti P
    Eur J Endocrinol; 2009 Nov; 161(5):737-45. PubMed ID: 19713424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adrenal androgen excess and body mass index in polycystic ovary syndrome.
    Moran C; Arriaga M; Arechavaleta-Velasco F; Moran S
    J Clin Endocrinol Metab; 2015 Mar; 100(3):942-50. PubMed ID: 25514100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adipocyte fatty acid-binding protein is associated with markers of obesity, but is an unlikely link between obesity, insulin resistance, and hyperandrogenism in polycystic ovary syndrome women.
    Möhlig M; Weickert MO; Ghadamgadai E; Machlitt A; Pfüller B; Arafat AM; Pfeiffer AF; Schöfl C
    Eur J Endocrinol; 2007 Aug; 157(2):195-200. PubMed ID: 17656598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Higher risk of type 2 diabetes in women with hyperandrogenic polycystic ovary syndrome.
    Persson S; Elenis E; Turkmen S; Kramer MS; Yong EL; Poromaa IS
    Fertil Steril; 2021 Sep; 116(3):862-871. PubMed ID: 34053678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-alcoholic fatty liver disease is associated with insulin resistance and lipid accumulation product in women with polycystic ovary syndrome.
    Macut D; Tziomalos K; Božić-Antić I; Bjekić-Macut J; Katsikis I; Papadakis E; Andrić Z; Panidis D
    Hum Reprod; 2016 Jun; 31(6):1347-53. PubMed ID: 27076501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polycystic ovary syndrome with hyperandrogenism as a risk factor for non-obese non-alcoholic fatty liver disease.
    Kim JJ; Kim D; Yim JY; Kang JH; Han KH; Kim SM; Hwang KR; Ku SY; Suh CS; Kim SH; Choi YM
    Aliment Pharmacol Ther; 2017 Jun; 45(11):1403-1412. PubMed ID: 28370150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular signature of adipose tissue in patients with both non-alcoholic fatty liver disease (NAFLD) and polycystic ovarian syndrome (PCOS).
    Baranova A; Tran TP; Afendy A; Wang L; Shamsaddini A; Mehta R; Chandhoke V; Birerdinc A; Younossi ZM
    J Transl Med; 2013 May; 11():133. PubMed ID: 23721173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PCOS is associated with increased CD11c expression and crown-like structures in adipose tissue and increased central abdominal fat depots independent of obesity.
    Huang ZH; Manickam B; Ryvkin V; Zhou XJ; Fantuzzi G; Mazzone T; Sam S
    J Clin Endocrinol Metab; 2013 Jan; 98(1):E17-24. PubMed ID: 23118428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.